Sort   by:  
 Page size 
UnknownSARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
Not available
S-EPMC8079668 | biostudies-literature
UnknownFirst characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017-2020.
Not available
S-EPMC8890659 | biostudies-literature
UnknownSARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals.
Not available
S-EPMC8142077 | biostudies-literature
UnknownEffectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
Not available
S-EPMC8117967 | biostudies-literature
UnknownEffects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.
Not available
S-EPMC10404859 | biostudies-literature
UnknownCOVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar.
Not available
S-EPMC9295939 | biostudies-literature
UnknownPopulation immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study.
Not available
S-EPMC10393554 | biostudies-literature
UnknownAssessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.
Not available
S-EPMC8803198 | biostudies-literature
UnknownImmune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.
Not available
S-EPMC9634858 | biostudies-literature
UnknownAssessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting.
Not available
S-EPMC7799253 | biostudies-literature
Sort   by:  
 Page size